Market By Product, Application, Technology, End-user And Geography | Forecast 2019-2028
After a detailed analysis, Triton Market Research has concluded that the molecular point of care diagnostics market is expected to display an upward trend in terms of revenue. In addition, it is estimated to grow at a CAGR of 14.05% during the forecasting years 2019 to 2028. The market, that accounted for $2004.43 million in 2018, is expected to reach $7398.82 million by 2028.
Molecular point of care can be said as one of the advanced diagnostic techniques. It works at a molecular level by identifying the signs of DNA, RNA or protein of the disease in the sample. As it is a point of care diagnostic technique, the tests and results are found on the site and there is no need to send samples to laboratories for testing. When comparing parameters such as the speed of diagnosis and accuracy, it comes at the top compared with another diagnostic testing. It is an upcoming sector and various developments are taking place in the field. During the COVID-19 crisis, various companies have developed their molecular point of care diagnostic kits; for example, Abbot launched Abbott ID NOW COVID-19 test in March 2020.
We provide additional customization based on your specific requirements. Request For Customization
The molecular point of care diagnostics market report from Triton gives a detailed analysis of the market definition, key insight, Porter’s five force analysis, market attractiveness index, vendor scorecard & regulatory framework.
Infectious diseases or communicable diseases are growing. Infectious substances are produced mainly by microorganisms such as bacteria and viruses. These common pathogenic organisms exhibit easy access and communication between causative organism and host that can spread from one person to another, directly or indirectly. Thus the need for advanced diagnostics to detect the disease early on increases.
In addition, an estimated 9.60 million people died from the different causes of cancer in 2018, a significant rise from 8.90 million deaths in 2016, according to WHO. By 2030, the global figure is projected to increase to 21.7 million new cases of cancer and 13 million deaths from cancer. With a growing need to extend the life expectancy and the urgent need to combat this, antagonistic concerns have and will continue to push the global care point market for molecular diagnostics significantly.
A key opportunity for the market is the innovation that helps the market adoption rates. Due to very high prices and restricted detection capabilities, the adoption of molecular diagnostics PoC systems has been largely restricted. However, the industry is now at the cusp of a paradigm change to newer molecular diagnostic tests, which have the potential to be substantially cheaper while increasing the number of targets per individual tests via high multiplexing capabilities simultaneously.
High capital requirements and lack of high complexity test centers are major constraints that impact the market negatively. Costly instruments are the prime reason for the high requirement for capital, which indicates that the size of the capital investment required, may change according to the scale and abilities of the developed laboratory. The cost of instrument sequencing can vary from $XX to $XX. Although the global market for molecular diagnostics has tremendous potential, the high demand for capital expenditure hampers the expansion of global penetration and thus challenges the growth of the molecular treatment market globally.
Geographies covered for the molecular point of care diagnostics market:
o         North America: United States and Canada
o         Europe: United Kingdom, Germany, France, Italy, Spain, Russia and Rest of Europe
o         Asia-Pacific: China, Japan, India, South Korea, ASEAN countries, Australia & New Zealand and Rest of Asia-Pacific
o         Latin America: Brazil, Mexico and Rest of Latin America
o         The Middle East and Africa: United Arab Emirates, Turkey, Saudi Arabia, South Africa and Rest of the Middle East & Africa
The molecular point of care diagnostics market, in this report, is segmented as:
•          Product is sub segmented into:
o         Assays
o         Instruments
o         Software
•          Application is sub segmented into:
o         Infectious Disease
•          Respiratory
•          Hospital-Acquired Infections
•          Sexually-Transmitted Infections
•          Gastrointestinal infections
o         Oncology
o         Prenatal
o         Others
•          Technology is sub segmented into:
o         Polymerase Chain Reaction (PCR)
•          Real-time PCR (q-PCR)
•          Digital PCR (d-PCR)
o         Isothermal Nucleic Acid Amplification Technology
o         Other
•          End-user is sub segmented into:
o         Hospital
o         Clinics
o         Diagnostic Centers
o         Others
Major key players engaged in the molecular point of care diagnostics market are Biomerieux SA, Abbott, Biocartis, F Hoffmann-La Roche Ltd, Qiagen, Danaher, QuantuMDx Group Ltd, Luminex Corporation, Quidel Corporation, Hologic Inc, Spartan Biosciences Inc, Abacus Diagnostica, DiaSorin SpA, Bio-Rad Laboratories Inc and Mesa Biotech. The strategic analysis for each of these companies in the molecular point of care diagnostics market is covered in detail.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET - SUMMARY
2. INDUSTRY OUTLOOK
2.1. MARKET DEFINITION
2.2. KEY INSIGHTS
2.2.1.  FDA ISSUED EMERGENCY USE AUTHORIZATION DUE TO COVID 19 PANDEMIC
2.2.2.  INCREASED GERIATRIC POPULATION REQUIRES MORE DIAGNOSTIC SERVICES
2.2.3.  NORTH AMERICA REGION LEADS THE MARKET
2.2.4.  OPPORTUNITIES FROM EMERGING COUNTRIES FOR THE MARKET
2.2.5.  HYBRIDIZATION OF AVAILABLE TECHNOLOGIES IS A PROMISING TREND
2.3. PORTER’S FIVE FORCE ANALYSIS
2.3.1.  THREAT OF NEW ENTRANTS
2.3.2.  THREAT OF SUBSTITUTE
2.3.3.  BARGAINING POWER OF SUPPLIERS
2.3.4.  BARGAINING POWER OF BUYERS
2.3.5.  THREAT OF COMPETITIVE RIVALRY
2.4. MARKET ATTRACTIVENESS INDEX
2.5. VENDOR SCORECARD
2.6. REGULATORY FRAMEWORK
2.6.1.  UNITED STATES
2.6.2.  EUROPE
2.6.3.  ASIA-PACIFIC
2.6.3.1. CHINA
2.6.3.2. JAPAN
2.7. MARKET DRIVERS
2.7.1.  DEMAND FOR DIAGNOSING PRESENCE OF SARS COV-2
2.7.2.  INCREASING DEMAND FOR NON-INVASIVE DIAGNOSIS
2.7.3.  RISE IN THE NUMBER OF DISEASES
2.8. MARKET RESTRAINTS
2.8.1.  HIGH CAPITAL REQUIREMENT
2.9. MARKET OPPORTUNITIES
2.9.1.  SPENDING ON RESEARCH & DEVELOPMENT
2.9.2.  INNOVATIONS IN THE MARKET
2.10. MARKET CHALLENGES
2.10.1. LACK OF HIGH COMPLEXITY TESTING CENTERS
3. GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET OUTLOOK – BY PRODUCT
3.1. ASSAYS
3.2. INSTRUMENTS
3.3. SOFTWARE
4. GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET OUTLOOK - BY APPLICATION
4.1. INFECTIOUS DISEASE
4.1.1.  RESPIRATORY
4.1.2.  HOSPITAL-ACQUIRED INFECTIONS
4.1.3.  SEXUALLY-TRANSMITED INFECTIONS
4.1.4.  GASTROINTESTINAL INFECTIONS
4.2. ONCOLOGY
4.3. PRENATAL
4.4. OTHERS
5. GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET OUTLOOK - BY TECHNOLOGY
5.1. POLYMERASE CHAIN REACTION
5.1.1.  REAL-TIME PCR (Q-PCR)
5.1.2.  DIGITAL PCR (D-PCR)
5.2. ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
5.3. OTHER
6. GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET OUTLOOK - BY END-USER
6.1. HOSPITAL
6.2. CLINICS
6.3. DIAGNOSTIC CENTERS
6.4. OTHERS
7. GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET – REGIONAL OUTLOOK
7.1. NORTH AMERICA
7.1.1.  MARKET BY PRODUCT
7.1.2.  MARKET BY APPLICATION
7.1.2.1. MARKET BY INFECTIOUS DISEASE
7.1.3.  MARKET BY TECHNOLOGY
7.1.3.1. MARKET BY POLYMERASE CHAIN REACTION
7.1.4.  MARKET BY END-USER
7.1.5.  COUNTRY ANALYSIS
7.1.5.1. UNITED STATES
7.1.5.2. CANADA
7.2. EUROPE
7.2.1.  MARKET BY PRODUCT
7.2.2.  MARKET BY APPLICATION
7.2.2.1. MARKET BY INFECTIOUS DISEASE
7.2.3.  MARKET BY TECHNOLOGY
7.2.3.1. MARKET BY POLYMERASE CHAIN REACTION
7.2.4.  MARKET BY END-USER
7.2.5.  COUNTRY ANALYSIS
7.2.5.1. UNITED KINGDOM
7.2.5.2. GERMANY
7.2.5.3. FRANCE
7.2.5.4. SPAIN
7.2.5.5. ITALY
7.2.5.6. RUSSIA
7.2.5.7. REST OF EUROPE
7.3. ASIA-PACIFIC
7.3.1.  MARKET BY PRODUCT
7.3.2.  MARKET BY APPLICATION
7.3.2.1. MARKET BY INFECTIOUS DISEASE
7.3.3.  MARKET BY TECHNOLOGY
7.3.3.1. MARKET BY POLYMERASE CHAIN REACTION
7.3.4.  MARKET BY END-USER
7.3.5.  COUNTRY ANALYSIS
7.3.5.1. CHINA
7.3.5.2. JAPAN
7.3.5.3. INDIA
7.3.5.4. SOUTH KOREA
7.3.5.5. ASEAN COUNTRIES
7.3.5.6. AUSTRALIA & NEW ZEALAND
7.3.5.7. REST OF ASIA-PACIFIC
7.4. LATIN AMERICA
7.4.1.  MARKET BY PRODUCT
7.4.2.  MARKET BY APPLICATION
7.4.2.1. MARKET BY INFECTIOUS DISEASE
7.4.3.  MARKET BY TECHNOLOGY
7.4.3.1. MARKET BY POLYMERASE CHAIN REACTION
7.4.4.  MARKET BY END-USER
7.4.5.  COUNTRY ANALYSIS
7.4.5.1. BRAZIL
7.4.5.2. MEXICO
7.4.5.3. REST OF LATIN AMERICA
7.5. MIDDLE EAST AND AFRICA
7.5.1.  MARKET BY PRODUCT
7.5.2.  MARKET BY APPLICATION
7.5.2.1. MARKET BY INFECTIOUS DISEASE
7.5.3.  MARKET BY TECHNOLOGY
7.5.3.1. MARKET BY POLYMERASE CHAIN REACTION
7.5.4.  MARKET BY END-USER
7.5.5.  COUNTRY ANALYSIS
7.5.5.1. UNITED ARAB EMIRATES
7.5.5.2. TURKEY
7.5.5.3. SAUDI ARABIA
7.5.5.4. SOUTH AFRICA
7.5.5.5. REST OF MIDDLE EAST & AFRICA
8. COMPETITIVE LANDSCAPE
8.1. ABBOTT
8.2. ABACUS DIAGNOSTICA
8.3. BIOMERIEUX SA
8.4. BIOCARTIS
8.5. DANAHER
8.6. DIASORIN SPA
8.7. BIO-RAD LABORATORIES INC
8.8. F HOFFMANN-LA ROCHE LTD
8.9. LUMINEX CORPORATION
8.10. HOLOGIC INC
8.11. MESA BIOTECH
8.12. SPARTAN BIOSCIENCES INC
8.13. QUANTUMDX GROUP LTD
8.14. QUIDEL CORPORATION
8.15. QIAGEN
9. METHODOLOGY & SCOPE
9.1. RESEARCH SCOPE
9.2. SOURCES OF DATA
9.3. RESEARCH METHODOLOGY
TABLE 1: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY GEOGRAPHY, 2019-2028 (IN $ MILLION)
TABLE 2: EMERGENCY USE AUTHORIZATION FOR DIAGNOSTICS BY FDA
TABLE 3: MARKET ATTRACTIVENESS INDEX
TABLE 4: VENDOR SCORECARD
TABLE 5: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (IN $ MILLION)
TABLE 6: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (IN $ MILLION)
TABLE 7: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY INFECTIOUS DISEASE, 2019-2028 (IN $ MILLION)
TABLE 8: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (IN $ MILLION)
TABLE 9: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY POLYMERASE CHAIN REACTION, 2019-2028 (IN $ MILLION)
TABLE 10: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY END-USER, 2019-2028 (IN $ MILLION)
TABLE 11: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY GEOGRAPHY, 2019-2028 (IN $ MILLION)
TABLE 12: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, 2019-2028 (IN $ MILLION)
TABLE 13: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (IN $ MILLION)
TABLE 14: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (IN $ MILLION)
TABLE 15: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY INFECTIOUS DISEASE, 2019-2028 (IN $ MILLION)
TABLE 16: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (IN $ MILLION)
TABLE 17: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY POLYMERASE CHAIN REACTION, 2019-2028 (IN $ MILLION)
TABLE 18: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY END-USER, 2019-2028 (IN $ MILLION)
TABLE 19: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, 2019-2028 (IN $ MILLION)
TABLE 20: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (IN $ MILLION)
TABLE 21: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (IN $ MILLION)
TABLE 22: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY INFECTIOUS DISEASE, 2019-2028 (IN $ MILLION)
TABLE 23: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (IN $ MILLION)
TABLE 24: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY POLYMERASE CHAIN REACTION, 2019-2028 (IN $ MILLION)
TABLE 25: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY END-USER, 2019-2028 (IN $ MILLION)
TABLE 26: ASIA-PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, 2019-2028 (IN $ MILLION)
TABLE 27: ASIA-PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (IN $ MILLION)
TABLE 28: ASIA-PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (IN $ MILLION)
TABLE 29: ASIA-PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY INFECTIOUS DISEASE, 2019-2028 (IN $ MILLION)
TABLE 30: ASIA-PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (IN $ MILLION)
TABLE 31: ASIA-PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY POLYMERASE CHAIN REACTION, 2019-2028 (IN $ MILLION)
TABLE 32: ASIA-PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY END-USER, 2019-2028 (IN $ MILLION)
TABLE 33: LATIN AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, 2019-2028 (IN $ MILLION)
TABLE 34: LATIN AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (IN $ MILLION)
TABLE 35: LATIN AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (IN $ MILLION)
TABLE 36: LATIN AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY INFECTIOUS DISEASE, 2019-2028 (IN $ MILLION)
TABLE 37: LATIN AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (IN $ MILLION)
TABLE 38: LATIN AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY POLYMERASE CHAIN REACTION, 2019-2028 (IN $ MILLION)
TABLE 39: LATIN AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY END-USER, 2019-2028 (IN $ MILLION)
TABLE 40: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, 2019-2028 (IN $ MILLION)
TABLE 41: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (IN $ MILLION)
TABLE 42: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (IN $ MILLION)
TABLE 43: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY INFECTIOUS DISEASE, 2019-2028 (IN $ MILLION)
TABLE 44: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (IN $ MILLION)
TABLE 45: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY POLYMERASE CHAIN REACTION, 2019-2028 (IN $ MILLION)
TABLE 46: MIDDLE EAST AND AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY END-USER, 2019-2028 (IN $ MILLION)
FIGURE 1: PORTER’S FIVE FORCE ANALYSIS
FIGURE 2: COST COMPARISON BETWEEN LABORATORY, IMMUNOASSAY AND MOLECULAR POC DIAGNOSTIC TESTS
FIGURE 3: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY ASSAYS, 2019-2028 (IN $ MILLION)
FIGURE 4: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY INSTRUMENTS, 2019-2028 (IN $ MILLION)
FIGURE 5: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY SOFTWARE, 2019-2028 (IN $ MILLION)
FIGURE 6: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY INFECTIOUS DISEASE, 2019-2028 (IN $ MILLION)
FIGURE 7: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY RESPIRATORY, 2019-2028 (IN $ MILLION)
FIGURE 8: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY HOSPITAL-ACQUIRED INFECTIONS, 2019-2028 (IN $ MILLION)
FIGURE 9: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY SEXUALLY-TRANSMITTED INFECTIONS, 2019-2028 (IN $ MILLION)
FIGURE 10: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY GASTROINTESTINAL INFECTIONS, 2019-2028 (IN $ MILLION)
FIGURE 11: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY ONCOLOGY, 2019-2028 (IN $ MILLION)
FIGURE 12: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY PRENATAL, 2019-2028 (IN $ MILLION)
FIGURE 13: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY OTHERS, 2019-2028 (IN $ MILLION)
FIGURE 14: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY POLYMERASE CHAIN REACTION, 2019-2028 (IN $ MILLION)
FIGURE 15: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY REAL-TIME PCR (Q-PCR), 2019-2028 (IN $ MILLION)
FIGURE 16: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY DIGITAL PCR (D-PCR), 2019-2028 (IN $ MILLION)
FIGURE 17: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, 2019-2028 (IN $ MILLION)
FIGURE 18: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY OTHER, 2019-2028 (IN $ MILLION)
FIGURE 19: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY HOSPITAL, 2019-2028 (IN $ MILLION)
FIGURE 20: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY CLINICS, 2019-2028 (IN $ MILLION)
FIGURE 21: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY DIAGNOSTIC CENTERS, 2019-2028 (IN $ MILLION)
FIGURE 22: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY OTHERS, 2019-2028 (IN $ MILLION)
FIGURE 23: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2018 & 2028 (IN %)
FIGURE 24: UNITED STATES MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 25: CANADA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 26: UNITED KINGDOM MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 27: GERMANY MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 28: FRANCE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 29: SPAIN MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 30: ITALY MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 31: RUSSIA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 32: REST OF EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 33: CHINA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 34: JAPAN MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 35: INDIA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 36: SOUTH KOREA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 37: ASEAN COUNTRIES MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 38: AUSTRALIA & NEW ZEALAND MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 39: REST OF ASIA-PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 40: BRAZIL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 41: MEXICO MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 42: REST OF LATIN AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 43: UNITED ARAB EMIRATES MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 44: TURKEY MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 45: SAUDI ARABIA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 46: SOUTH AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 47: REST OF MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)